¹ÙÀÌ¿ÀÀǾàǰ CMO ¹× CRO ½ÃÀå : ¿ø·áº°, ¼ºñ½ºº°, Á¦Ç°º°, Áö¿ªº°
Biopharmaceutical CMO and CRO Market, By Source, By Service, and By Product, and By Geography
»óǰÄÚµå
:
1747611
¸®¼Ä¡»ç
:
Coherent Market Insights
¹ßÇàÀÏ
:
2025³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¹ÙÀÌ¿ÀÀǾàǰ CMO ¹× CRO ½ÃÀåÀº 2025³â¿¡´Â 406¾ï ´Þ·¯·Î ÃßÁ¤µÇ°í, 2032³â¿¡´Â 606¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â CAGR 5.9%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
º¸°í ¹üÀ§ |
º¸°í¼ ¼¼ºÎÁ¤º¸ |
±âÁØ ¿¬µµ |
2024³â |
½ÃÀå ±Ô¸ð(2025³â) |
406¾ï ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ |
2020-2024³â |
¿¹Ãø ±â°£ |
2025-2032³â |
¿¹Ãø ±â°£ CAGR(2025-2032³â) : |
5.90% |
¿¹Ãø ±Ý¾×(2032³â) |
606¾ï 5,000¸¸ ´Þ·¯ |
¹ÙÀÌ¿ÀÀǾàǰ CMO(ÀǾàǰ Á¦Á¶ ¼öʱâ°ü)´Â ÀǾàǰ Á¦Á¶ ¼ºñ½ººÎÅÍ ÆÐŰ¡¿¡ À̸£±â±îÁö ¹ÙÀÌ¿ÀÀǾàǰ ºÐ¾ßÀÇ ´Ù¸¥ ±â¾÷¿¡ ¼ºñ½º¸¦ Á¦°øÇÏ´Â ¼öŹ ±â¹Ý ±â¾÷ÀÔ´Ï´Ù. ÇÑÆí, CRO(ÀǾàǰ °³¹ß ¾÷¹« ¼öŹ ±â°ü)¶õ, ¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷¿¡ ¿¬±¸ ¼ºñ½º¸¦ À§Å¹ÇÑ´Ù°í ÇÏ´Â ÇüÅ·Π¼Æ÷Æ®¸¦ Á¦°øÇÏ´Â ±â¾÷ÀÔ´Ï´Ù.
½ÃÀå ¿ªÇÐ :
¸¸¼º Áúȯ Áõ°¡, â¾à °³¹ß Áõ°¡, »ý¹° Á¦Á¦ ¹× ¹ÙÀÌ¿À½Ã¹Ð·¯ ¼ö¿ä Áõ°¡, ¾Æ¿ô¼Ò½Ì Áõ°¡ Ãß¼¼, ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡, ¹ÙÀÌ¿ÀÀǾàǰ »ê¾÷ÀÇ ±Þ¼ºÀåÀº ¼¼°è ¹ÙÀÌ¿À ÀǾàǰ CMO ¹× CRO ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù.
¿¹¸¦ µé¾î, 2023³â 2¿ù, ·ç³ªÆ÷¾î¿Í ½Ã·Î³ª Dx´Â Àü·«Àû Á¦ÈÞ¸¦ ¹ßÇ¥Çϰí, ½Ã·Î³ª Dx´Â ·ç³ªÆ÷¾îÀÇ ÁÖ·Â Á¦Ç°ÀÎ COMET °ø°£ »ý¹°ÇÐ Ç÷§ÆûÀ» ¼ºñ½º·Î Á¦°øÇÏ´Â ¹Ì±¹ ÃÖÃÊÀÇ CRO(ÀǾàǰ °³¹ß ¾÷¹« ¼öʱâ°ü)°¡ µË´Ï´Ù. COMET´Â ½Ã·Î³ª DxÀÇ ¿¬±¸ ¼ºñ½º Æ÷Æ®Æú¸®¿À¸¦ º¸¿ÏÇÏ¿© ´Ù¾çÇÑ ºÐ¾ßÀÇ ¿¬±¸ÀÚ ¹× ¹ÙÀÌ¿ÀÆÄ¸¶ ÆÀÀÇ ¿ä±¸¿¡ ´ëÀÀÇÕ´Ï´Ù. COMET´Â ´Ù¾çÇÑ ºÐ¾ß, ¿¬±¸ ¹× ÀǾàǰ °³¹ßÀÇ ¸ðµç ´Ü°è¿¡ ÀÖ¾î¼, Æø³ÐÀº ¿¬±¸ ¿ëµµ¸¦ Á¦°øÇÕ´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
- º» º¸°í¼´Â ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ CMO ¹× CRO ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð ¹× ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.
- ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡¼ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÇô ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¿¡ ´ëÇØ ¼³¸íÇϰí ÀÖ½À´Ï´Ù.
- ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ ÀλçÀÌÆ®µµ Á¦°øÇÕ´Ï´Ù.
- ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅÍ¿¡ ±Ù°ÅÇØ, ¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ CMO ¹× CRO ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.
- º» º¸°í¼ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ ¹× ±â¾÷ÀÇ °æ¿µÁøÀº Àå·¡ÀÇ Á¦Ç° Ãâ½Ã, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ °üÇÑ Á¤º¸¿¡ ±Ù°ÅÇÑ ÀÇ»ç °áÁ¤À» ½Ç½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù.
- ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ CMO ¹× CRO ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.
- ÀÌÇØ°ü°èÀÚ´Â ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ CMO ¹× CRO ½ÃÀåÀ» ºÐ¼®ÇÒ ¶§ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷ :
Á¦1Àå Á¶»çÀÇ ¸ñÀû ¹× ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
- º¸°í¼ ¼³¸í
- ÁÖ¿ä ¿ä¾à
- ÀϰüµÈ ±âȸ Áöµµ(COM)
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦ ¹× µ¿Ç⠺м®
- ½ÃÀå ¿ªÇÐ
- ¼¼°è ¾Æ¿ô¼Ò½ÌÀÇ Æ®·»µå°¡ È®´ë
- ¾ö°ÝÇÑ ±ÔÁ¦ Ʋ
- ¹ÙÀÌ¿ÀÀǾàǰ »ê¾÷ÀÇ ±Þ¼ÓÇÑ ¼ºÀå
- ¿µÇ⠺м®
- ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- ±ÔÁ¦ ½Ã³ª¸®¿À
- Á¦Ç° Ãâ½Ã ¹× ½ÂÀÎ
- PEST ºÐ¼®
- Porter's Five Forces ºÐ¼®
- ÇÕº´ ¹× Àμö ½Ã³ª¸®¿À
Á¦4Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ CMO ¹× CRO ½ÃÀå : ¿ø·áº°(2020-2032³â)
Á¦5Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ CMO ¹× CRO ½ÃÀå : ¼ºñ½ºº°(2020-2032³â)
Á¦6Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ CMO ¹× CRO ½ÃÀå : Á¦Ç°º°(2020-2032³â)
- ¹ÙÀÌ¿À·ÎÁ÷½º
- ¹ÙÀÌ¿À½Ã¹Ð·¯
Á¦7Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ CMO ¹× CRO ½ÃÀå : Áö¿ªº°(2020-2032³â)
- ºÏ¹Ì
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ¾Æ¸£ÇîÆ¼³ª
- ¸ß½ÃÄÚ
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- À¯·´
- µ¶ÀÏ
- ¿µ±¹
- ½ºÆäÀÎ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- È£ÁÖ
- Çѱ¹
- ASEAN
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- 秵- GCC ±¹°¡
- À̽º¶ó¿¤
- ±âŸ Áßµ¿
- ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«
- ºÏ¾ÆÇÁ¸®Ä«
- Áß¾Ó ¾ÆÇÁ¸®Ä«
Á¦8Àå °æÀï ±¸µµ
- Allphase Clinical Research
- AlcheraBio
- Alcami
- Akos Urgent Care
- Agilent
- AGC Biologics
- Affinity Life Sciences, Inc.
- Actimus Bio
- ACI Clinical
- Accumedix, Inc.
- Absorption Systems
- A10 Clinical Solutions
- Albuquerque Clinical Trials(ACT)
- Ajinomoto Bio-Pharma Services
- Advanced Clinical Services LLC
- ACM Global Laboratories
- Accelerated Enrollment Solutions
- AbbVie Contract Manufacturing
- Advanced BioScience Laboratories
- Advanced Clinical Research Institute
- Alliance for Clinical Trials in Oncology
Á¦9Àå ¼½¼Ç
AJY
¿µ¹® ¸ñÂ÷
Biopharmaceutical CMO and CRO Market is estimated to be valued at USD 40.6 Bn in 2025 and is expected to reach USD 60.65 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032.
Report Coverage |
Report Details |
Base Year: |
2024 |
Market Size in 2025: |
USD 40.6 Bn |
Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: |
5.90% |
2032 Value Projection: |
USD 60.65 Bn |
Biopharmaceutical CMO (Contract Manufacturing Organization) is a company that serves other companies in the biopharmaceutical sector on a contract basis to offer services ranging from drug manufacturing services to packaging. While, Contract Research Organization (CRO) is a company that provides support to biopharmaceutical companies in the form of research services outsourced on a contract basis.
Market Dynamics:
Rise in burden of chronic diseases, increasing drug discovery and development, increasing demand for biologics and biosimilars, growing trend of outsourcing, increasing investment in research and development and the rapid growth of the biopharmaceutical industry are major factors expected to augment the growth of the global biopharmaceutical CMO and CRO market.
For instance, in February 2023, Lunaphore and Sirona Dx announced a strategic collaboration in which Sirona Dx will become the first US-based Contract Research Organization (CRO) to offer Lunaphore's flagship COMET spatial biology platform as a service. A COMET will complement Sirona Dx's portfolio of research service offerings to meet the needs of researchers and biopharma teams across various disciplines. COMET has a wide range of research applications across multiple disciplines and all stages of research and drug development.
Key features of the study:
- This report provides in-depth analysis of the global biopharmaceutical CMO and CRO market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global biopharmaceutical CMO and CRO market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include AlcheraBio, Alcami, Akos Urgent Care, Agilent, AGC Biologics, Affinity Life Sciences, Inc., Actimus Bio, ACI Clinical, Accumedix, Inc., Allphase Clinical Research, Absorption Systems, A10 Clinical Solutions, Albuquerque Clinical Trials (ACT), Ajinomoto Bio-Pharma Services, Advanced Clinical Services LLC, ACM Global Laboratories, Accelerated Enrollment Solutions, AbbVie Contract Manufacturing, Advanced BioScience Laboratories, Advanced Clinical Research Institute, and Alliance for Clinical Trials in Oncology, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global biopharmaceutical CMO and CRO market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biopharmaceutical CMO and CRO market.
Detailed Segmentation:
- Global Biopharmaceutical CMO and CRO Market, By Source:
- Global Biopharmaceutical CMO and CRO Market, By Service:
- Contract Manufacturing
- Contract Research
- Global Biopharmaceutical CMO and CRO Market, By Product:
- Global Biopharmaceutical CMO and CRO Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles:
- Allphase Clinical Research
- AlcheraBio
- Alcami
- Akos Urgent Care
- Agilent
- AGC Biologics
- Affinity Life Sciences, Inc.
- Actimus Bio
- ACI Clinical
- Accumedix, Inc.
- Absorption Systems
- A10 Clinical Solutions
- Albuquerque Clinical Trials (ACT)
- Ajinomoto Bio-Pharma Services
- Advanced Clinical Services LLC
- ACM Global Laboratories
- Accelerated Enrollment Solutions
- AbbVie Contract Manufacturing
- Advanced BioScience Laboratories
- Advanced Clinical Research Institute
- Alliance for Clinical Trials in Oncology
Table of Contents:
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Source
- Market Snapshot, By Service
- Market Snapshot, By Product
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Growing trend of outsourcing across the globe
- Stringent regulatory framework
- Rapid growth of the biopharmaceutical industry
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Biopharmaceutical CMO and CRO Market, By Source, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Mammalian
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Non-mammalian
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
5. Global Biopharmaceutical CMO and CRO Market, By Service, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Contract Manufacturing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Contract Research
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
6. Global Biopharmaceutical CMO and CRO Market, By Product, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Biosimilars
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
7. Global Biopharmaceutical CMO and CRO Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Service, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Service, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Service, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Service, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Service, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Service, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Allphase Clinical Research
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AlcheraBio
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alcami
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Akos Urgent Care
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Agilent
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AGC Biologics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Affinity Life Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Actimus Bio
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ACI Clinical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Accumedix, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Absorption Systems
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- A10 Clinical Solutions
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Albuquerque Clinical Trials (ACT)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ajinomoto Bio-Pharma Services
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Advanced Clinical Services LLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ACM Global Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Accelerated Enrollment Solutions
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Contract Manufacturing
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Advanced BioScience Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Advanced Clinical Research Institute
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alliance for Clinical Trials in Oncology
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
9. Section
- Research Methodology
- About us
°ü·ÃÀÚ·á